# NUTRITIONAL SCREENING IN ONCOLOGY OUTPATIENTS TREATED WITH ORAL ANTINEOPLASTIC DRUGS IN A PHARMACEUTICAL CARE CONSULTATION



M.H. García Lagunar, A.M. Chica Marchal, I. Muñoz García, M.D.R. Gutiérrez Cívicos, E. Ferris Villanueva, R. Guerrero Bautista, A. García Márquez, A. C. Viney, D. Lacruz Guzmán, M. Martínez Penella.

Hospital General Universitario Santa Lucía. Farmacia Hospitalaria. Cartagena (Spain).

## BACKGROUND:

Oncology patients are susceptible to malnutrition and this is a risk factor for morbidity and mortality.

#### **PURPOSE:**

To evaluate the nutritional status in patients treated with oral chemotherapy in a tertiary hospital.

#### **MATERIAL AND METHODS:**

Preliminary study including all patients treated with oral antineoplastic drugs cited in the outpatient pharmaceutical care consultation during May 2015. Patients treated < 3 months were excluded.





#### Variables collected:

Age, sex, neoplasia, drug used, height, current weight, weight 3 months ago. Data were obtained from the interview and the clinical history.

We used the Malnutrition Universal Screening Tool (MUST).

#### **RESULTS: BMI** at the time of the consultation The interview was conducted 26.23±4.30 kg/m<sup>2</sup> **MUST** screening in 30 patients 2.67±0.83 points **BMI** previous (3 months before) 27.40±4.23 kg/m<sup>2</sup> 62.37±12.19 years 50.0% male 30.0% normal weight Neoplasia type 40.0% overweight Oral antineoplastic drug sarcoma 26.7% obesity class I prostate topotecan 3.3% obesity class II pancreatic temozolomide lymphona sorafenib lung 18 patients (60.0%) lost weight pazopanib kidney lenalidomide (mean lost 7.7±4.1%) hepatocarcinoma lapatinib glioma imatinib <5%: 5 patients gastric everolimus (2 normal weight + 3 overweight) cholangiocarcinoma erlotinib 5%-10%: 8 patients colon enzalutamide (2 normal weight + 4 overweight + breast ceritinib 1 obesity class I + 1 obesity class II) capecitabine/lapatinib capecitabine >10%: 5 patients 10 bexarotene (2 overweight + 3 obesity class I) abiraterone

### **CONCLUSION:**

Patients treated with oral chemotherapy are a group of risk of malnutrition. More than half of the patients lost weight during treatment, even in patients with normal weight.

Prospective studies should be conducted to confirm these results. It is important to know the nutritional impact using oral chemotherapy for preventing and managing malnutrition.

